(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Spots To Go Birdwatching All over the Planet - 2New method spots signs of Earth's primordial life in ancient rocks
- 3Instructions to Upgrade the Proficiency of Your Sunlight powered chargers
- 4Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- 5Most loved Occasion Dish: What Makes Your Merry Table?
- 10 Hints and Deceives to Expand Cell Phone Information Use: Capitalize on Your Information
- Figure out How to Forestall Tooth Staining
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- The Significance of Health Projects in Senior Protection.
- A Republican elected governor in California? It's not as far-fetched as it sounds.
- What's A Decent FICO rating?
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks
